Loading stock data…
$36.41+0.09 (+0.26%)
Pacira BioSciences, Inc.
Pacira BioSciences, Inc. in the Healthcare sector is trading at $36.41 with a market capitalization of $917M. Wall Street consensus targets $33.57 (7 analysts), implying a -7.8% move over the next 12 months. The stock is currently near its 52-week high of $36.46, remaining 50.8% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $192.40M↑ | $177.38M↓ | $196.87M↑ | $179.52M↓ | $181.10M |
| Gross Profit | $148.24M↑ | $140.96M↓ | $156.57M↑ | $145.24M↑ | $140.23M |
| Operating Income | $11.86M↑ | $4.63M↑ | -$10.92M↓ | $13.15M↑ | $9.13M |
| Net Income | $4.65M↑ | $2.92M↑ | $1.64M↓ | $5.43M↑ | -$4.85M |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupiva...